Hematopoietic SCT is an established treatment for a variety of hematological malignancies. 1 However, the antitumor effect relies partly on the conditioning regimen before transplantation, which is performed with high-dose chemotherapy with or without the use of TBI, a regimen that causes severe toxicity to the ovaries. 2 Successful pregnancies following TBI of more than 10 Gy have been reported, but they are extremely rare. [3] [4] [5] The aim of this study was to preserve ovarian function by ovarian shielding while undergoing TBI for hematopoietic SCT. 6 The subjects in this study were women under 40 years of age, who were undergoing allogeneic hematopoietic SCT, using a TBI-based regimen, and who desired to have children after transplantation. The study was approved by the Ethics committee of the University of Tokyo Hospital and all patients gave informed consent to participate in this study.
The preparative regimen was a combination of CY at 60 mg/kg/day for 2 days and TBI at 2 Gy twice daily for 3 days. In one patient, the dose of CY was reduced to 40 mg/ kg/day for 1 day and etoposide at 20 mg/kg/day for 2 days was added instead, because of impaired cardiac function before transplantation. The procedure of TBI with ovarian shielding was described in detail previously. 7 Briefly, patients were treated in a mobile box 600 mm wide Â 2000 mm long Â 400 mm high made of 10-mm thick polymethyl methacrylate. The box is capable of moving up to 250 cm forward and backward on the rails with a constant speed. Beam intensity and moving velocity defined dose rate in TBI. For ovarian shielding, abdominal magnetic resonance imaging and computed tomography were performed before TBI. The position of the ovaries was checked with a T2-weighted image of magnetic resonance imaging and was projected and marked onto the patient's skin. Transabdominal ultrasound on the day of treatment was performed for accurate positioning of the shields. A pair of columnar blocks (8 cm in height and 5 cm in diameter) was placed just above the patient's body.
We performed ovarian shielding on eight patients undergoing TBI as a conditioning regimen (Table 1) . Two had CML in first chronic phase and one had myelodysplastic syndrome. These patients had not received i.v. administration of antineoplastic agents before transplantation. Four patients had acute leukemia, two in first remission and two in second remission following a median of 6.5 cycles (range 5-15) of intensive chemotherapy. One patient had chronic active EB virus infection and received five cycles of chemotherapy before transplantation. Three patients without a history of i.v. chemotherapy had regular menstruation before transplantation, but the two patients in second remission of acute leukemia already had chemotherapy-induced amenorrhea. It was impossible to evaluate ovarian function before transplantation in the two patients who were in their first remission of acute leukemia and in the patient with chronic active EB virus infection, because leuprorelin had been administered to stop menstruation. The donors were matched unrelated donors in five cases, HLA-identical siblings in two cases and an HLA2-locus-mismatched sibling in one case (Table 1) .
It was impossible to evaluate the possible infiltration of ovaries with leukemia, but the incidence of leukemic infiltration of ovaries is reported to be very low, except for patients with terminal stage leukemia. We did not include patients with active malignancy in this protocol. All eight patients demonstrated successful neutrophil engraftment at a median of 20 days (range 15-31) after transplantation and complete donor-type chimerism was confirmed. Grade II acute GVHD was observed in three patients and treated successfully with steroids (Table 2) . However, two of these patients developed extensive chronic GVHD, one of whom died of bronchiolitis obliterans 4 years after transplantation. One patient with ALL in second remission relapsed 7 months after transplantation. Chemotherapy was given combined with donor lymphocyte infusion, but eventually the patient died 17 months after transplantation. Another patient with AML in second remission had an isolated extramedullary relapse in the right breast 2 years after transplantation and achieved a third remission with local irradiation followed by chemotherapy. The other five patients are alive and well at a median follow-up of 18 months (range 12-68 months).
We have previously reported that two of the first three patients in this report recovered ovarian function 1 and 2 years after transplantation, respectively. 7 However, spontaneous recovery of ovarian function can occur without the use of ovarian shielding several years after transplantation, although the incidence is less than 15%. 8 Therefore, we could not exclude the possibility that ovarian recovery in the two patients would have occurred without ovarian shielding. Here we report that six of the eight patients showed ovarian recovery at a median of 15 months (range 6-24 months) after transplantation ( Table 2) . We did not give any hormone replacement treatments until recovery. Recovery of ovarian function was defined as the normalization of serum follicle-stimulating hormone (FSH) levels and the recovery of menstruation. One patient became pregnant at 4 years post transplantation and had an uncomplicated normal-term vaginal birth producing a healthy male baby (birth weight 2500 g) when she was 30 years old. One patient died without a recovery of ovarian function and another is alive but amenorrheic with an elevated follicle-stimulating hormone level 2 years after transplantation. The frequent and early recovery of ovarian function clearly showed the ability of ovarian shielding to preserve ovarian function.
In conclusion, ovarian shielding successfully preserved ovarian function in the majority of patients who underwent TBI without any apparent increased risk of relapse after transplantation. However, it may be prudent to exclude patients with active leukemia due to the decreased irradiation dose delivered to the ovaries and pelvis. Physicians should seek to preserve fertility in young female patients undergoing hematopoietic SCT by means of both ovarian shielding and the preservation of embryos or oocytes. 
